

ORIGINAL ARTICLE

Open Access

Four butyrolactones and diverse bioactive secondary metabolites from terrestrial *Aspergillus flavipes* MM2: isolation and structure determination

Mohamed MS Nagia^{1,3}, Mohammad Magdy El-Metwally², Mohamed Shaaban^{1,3*}, Soheir M El-Zalabani⁴ and Atef G Hanna¹

Abstract

The chemical constituents and biological activities of the terrestrial *Aspergillus flavipes* MM2 isolated from Egyptian rice hulls are reported. Seven bioactive compounds were obtained, of which one sterol: ergosterol (**1**), four butyrolactones: butyrolactone I (**2**), aspulvinone H (**3**), butyrolactone-V (**6**) and 4,4'-dihydroxypulvinone (**7**), along with 6-methylsalicylic acid (**4**) and the cyclopentenone analogue; terrien (**5**). Structures of the isolated compounds were deduced by intensive studies of their 1D & 2D NMR, MS data and comparison with related structures. The strain extract and the isolated compounds (**1-7**) were biologically studied against number of microbial strains, and brine shrimp for cytotoxicity. In this article, the taxonomical characterization of *A. flavipes* MM2 along with its upscale fermentation, isolation and structural assignment of the obtained bioactive metabolites, and evaluate their antimicrobial and cytotoxic activities were described.

Keywords: *Aspergillus flavipes* MM2, butyrolactones, biological studies

1. Background

In recent years, numerous metabolites possessing uncommon structures and potent bioactivity have been isolated from strains of bacteria and fungi collected from diverse environments, such as soils, animals, plants and sediments [1,2]. It was noted until Alexander Fleming discovered penicillin G from *Penicillium notatum* almost 83 years ago (1928) that fungal microorganisms suddenly became a hunting ground for novel drug leads [3,4]. Therefore, many pharmaceutical companies and research groups were motivated to start sampling and screening large collections of fungal strains for antibiotics [3,5,6]. Antimycotics [7,8], antivirals [9], anticancers [10] and pharmacologically active agents [11]. The *Aspergilli* represents a large diverse genus, containing ca. 180 filamentous fungal species, of substantial

pharmaceutical and commercial values [12]. In the research program to explore promising bioactive secondary metabolites from fungi, the terrestrial fungi, *Aspergillus flavipes* sp. isolate MM2 obtained from rice hulls, was investigated. The strain extract revealed the presence of promising antimicrobial activity against some pathogenic test organisms. Chemical screening (TLC investigation) of the strain extract showed numerous characteristic bands. Therefore, the strain was applied to large-scale fermentation by using Czapeck-Dox medium [13]. Working up of the strain cells produced ergosterol (**1**), while the filtrate extract afforded six diverse metabolic compounds: butyrolactone-I (**2**), aspulvinone H (**3**), 6-methylsalicylic acid (**4**), terrien (**5**), butyrolactone-V (**6**) and 4,4'-dihydroxypulvinone (**7**). The chemical structures of the isolated compounds (**1-7**) were identified with the help of NMR (1D & 2D) and mass spectrometry (ESI, EI, HRESIMS) (Figure 1). The antimicrobial activity was tested against some microorganisms and cytotoxicity was examined by using brine shrimp.

* Correspondence: mshaaba_99@yahoo.com

¹Division of Pharmaceutical Industries, Chemistry of Natural Compounds Department, National Research Centre, El-Beheos st. 33, Dokki, Cairo 12622, Egypt

Full list of author information is available at the end of the article




Figure 1 Structural formula of the investigated compounds (1-10).

2. Results and discussion

2.1. Taxonomical characterization of the fungal strain

The grown colonies of the fungal strain on Czapek-Dox medium showed bright whit-faint yellow colonies on the agar plate with a brown staining background [13]. The colonies are growing rather slowly, showing whitish from conidial masses, with brownish conidiophores shining through, reverse yellow-brown to red brown conidial heads spas, loosely columnar, conidiophores smooth-walled, pale yellow to light brown 2.4-3.2 μm in diameter. According to its morphological and microscopic characteristics and comparison with the taxonomical keys of Raper and Fennel [14], the strain was assigned as *A. flavipes* MM2.

2.2. Fermentation, working up and isolation

Based on the pre-screening study, the fungal strain *A. flavipes* MM2, cultivated on Czapeks-Dox for 10 days at 28°C, was shown to exhibit biological and chemical interest results. Therefore, the fungal strain was scaled up as 10 L culture using the same cultivating conditions applied for screening studies. After harvesting, both supernatant and mycelial cake phases were individually worked up. Purification of the mycelial extract using silica gel column, followed by washing the afforded major fraction by methanol and purification with Sephadex LH-20, yielded ergosterol (1). An application of the culture filtrate extract of *A. flavipes* MM2 to silica gel column chromatography, followed by diverse

chromatographic techniques, resulted in the isolation of six compounds: butyrolactone-I (**2**), aspulvinone H (**3**), methylsalicylic acid (**4**), terrein (**5**), butyrolactone-V (**6**) and 4,4'-dihydroxypulvinone (**7**).

2.3. Chemical characterization

2.3.1. Ergosterol (**1**)

Ergosterol (**1**) was obtained as colourless solid, showing UV activity during TLC, which turned violet on spraying with anisaldehyde/sulphuric acid and changed latter to blue. Structure of **1** was confirmed by different spectroscopic means (EI MS, ^1H , ^{13}C /APT NMR), chromatographic and comparison with literature [15,16]. Ergosterol plays an important role as inhibitor of lipid per-oxidation and showed strong DPPH radical scavenging activity as well [17,18], along with its cytotoxicity against HL-60 cells [19], MCF-7 cell line [20].

2.3.2. Butyrolactone-I (**2**)

The molecular weight of **2** was established as 424 Dalton by ESI MS, having the corresponding molecular formula $\text{C}_{24}\text{H}_{24}\text{O}_7$ and 13 unsaturation bonds. $^1\text{H}/\text{H,H}$ COSY NMR spectra of **2** showed two o-doublets ($J \sim 8.8$ Hz) each of 2H at δ 7.57 and 6.86, being for 1,4-disubstituted aromatic residue, along with three signals at δ 6.50, 6.48 and 6.40 representing 1,3,4-trisubstituted aromatic ring. A triplet signal of 1H was at δ 5.05, representing an olefinic methine linked to a doublet methylene signal appeared at δ 3.06. A 3H methoxy group (3.76); doublet of an AB methylene group (δ 3.42) attached to sp^2 system; and further two singlet methyls were visible at δ 1.65 and 1.56, representing a prenyl system.

According to the ^{13}C NMR/HMQC spectra of compound **2**, 22 carbon signals representing 24 carbons were displayed, including 2 carbonyls (δ 171.6 and 170.3), 2 sp^2 oxygenated carbons (δ 159.3, 155.0) of phenolic systems, along with 5 quaternary carbons (δ 139.6-123.1). Two 2CH sp^2 methine signals (130.4 and 116.6) for 1,4-disubstituted benzene ring beside to four sp^2 methines (δ 132.4-115.0). In the aliphatic region, signals for quaternary oxygenated methine (δ 86.8), methoxy (53.8), two methylenes (δ 39.6, 28.7) and two methyls (δ 25.9, 17.8) were assigned. Finally, structure of **2** was further deduced on the basis of HMBC experimental data, and comparison with literature as Butyrolactone-I [21,22]. Butyrolactone-I (**2**) was reported as a lipid lowering agent of Lovastatin \times [19,23,24], showing antiproliferative activity against colon, pancreatic carcinoma, human lung cancer and prostatic cancer [25-30] (Figure 2).

2.3.3. Aspulvinone H (**3**)

Based on the ESI MS, the molecular weight of **3** was deduced as 432 Dalton, and the corresponding

molecular formula as $\text{C}_{27}\text{H}_{28}\text{O}_5$, containing 14 unsaturation bonds, as closely related to butyrolactone-I (**2**). ^1H NMR spectrum of **3** showed six confused doublets each of 1H between δ 7.81 and 6.73, being of two unsymmetrical tri-substituted aromatic residues, and singlet methine at δ 6.22. A multiplet of 2H (δ 5.36), 4H of two attached sp^2 -bounded methylenes (δ 3.40-3.00) and multiplet signal (δ 1.75, 12H) of four sp^2 -linked methyls, assigning two prenyl systems. Based on the revealed NMR data and molecular formula, and search in Anti-Base [2], structure of **3** was fixed as aspulvinone H [31].


2.3.4. 6-Methylsalicylic acid (**4**)

According to the ESI mass spectra, the molecular weight of **4** was deduced as 152 Dalton. The ^1H NMR spectrum displayed three 1H resonating signals in the aromatic region (7.07, 6.63, 6.59), being of 1,2,3-trisubstituted aromatic ring ($J \sim 7.5$ -8.2 Hz) together with a singlet 3H of an aromatic bounded methyl (δ 2.56). Based on the ^{13}C NMR spectrum, compound **4** displayed eight carbon signals, including one quaternary (δ 176). Two further deep field quaternaries were visible (δ 162.7 and 142.7) for *a-peri*-hydroxy and methyl- sp^2 attached carbons, respectively. Three sp^2 methines (δ 132.2, 122.9, 115.1), one quaternary (δ 119.5) and a methyl signal (δ 23.3). In accordance, 2-Hydroxy-6-methyl-benzoic acid (**4**) was recognized [32,33] as anti-fungal substance [34], in addition to its analgesic [35], herbicidal [36] and antiacne activities [37].

2.3.5. Terrein (**5**)

The molecular weight of **5** was deduced as 154 Dalton ($\text{C}_8\text{H}_{10}\text{O}_3$), bearing four double bond equivalents. The ^1H NMR/H,H COSY spectrum of **5** showed two signals at δ 6.82 and 6.42 ($J \sim 15$ Hz), representing a *trans*-olefinic double bond, attached to a doublet methyl (δ 1.97), constructing a terminal propene system. A further singlet (δ 5.99) being of an olefinic methine and two doublets each of 1H (δ 4.67, 4.07, $J \sim 2.8$ Hz) corresponding to adjacent oxy-methines. According to ^{13}C NMR/HMQC spectra, eight carbon signals were displayed, including an acetophenone carbonyl (δ 205.6) and a deep field sp^2 quaternary carbon (δ 170.8); three sp^2 methines (δ 141.8, 126.4 and 125.9), two sp^3 oxy-methines (δ 82.4, 78.1) and one sp^2 -bounded methyl group (19.5).


A final interpretation of **5** was carried out by HMBC experiment (Figure 3), fixing the structure as 4,5-dihydroxy-3-propenyl-cyclopent-2-enone; terrein [38,39]. Terrein (**5**) has a hypopigmentary effect in Mel-Ab cells, and it is a strongly down-regulator of melanin synthesis by reducing tyrosinase production [40], and inhibit human platelet aggregation [41]. Terrein showed a strong antiproliferative effect on skin equivalents [42] and as proteasome inhibitor and anti-tumoral drug [43].



2.3.6. Butyrolactone-V (6)

The molecular weight of **6** was established as 440 Dalton ($C_{24}H_{24}O_8$), containing 13 double bond unsaturations. The 1H NMR/H,COSY spectrum of compound **6** revealed the presence 1,4-disubstituted (δ 7.54 and 6.85, $J \sim 8.8$ Hz), and unsymmetrical tri-substituted (m, δ 6.48) aromatic systems. A 1H dd signal (δ 5.02) of an oxygenated methine attached to a dd signal (δ 2.80) of a methylene group, confirming their ABX property. A singlet of methoxy group (δ 3.77), 2H methylene singlet (δ 3.40) flanked by two sp^2 systems, and two methyl singlets (δ 1.25 and 1.16), being of gem dimethyl groups were deduced.

Based on the ^{13}C NMR/HMQC spectra of compound **6**, two carbonyls (δ 171.5 and 170.3), two phenolic carbons (δ 159.4 and 153.3), β -quaternary carbon (δ 139.6) of an ester or lactone system were deduced. Two 2CH sp^2 signals (δ 130.4, 116.6), and 3CH sp^2 signals (δ 132.9, 130.4, 117.2), being of 1,4-disubstituted and




unsymmetric tri-substituted phenolic residues were shown. Two sp^3 quaternary oxy-carbons (δ 86.8 and 78.0), one oxy-methine (δ 70.4), one carbomethoxy (δ 53.9) and two methylenes (δ 39.0, 2.80) were visible. Two gem dimethyl signals attached to an oxygenated quaternary carbon were displayed (δ 25.9, 20.9).

Based on the above spectroscopic data and molecular formula, compound **6** exhibited a strong close structural similarity to butyrolactone-I (**2**). In accordance, three structural formulas were proposed according to search in AntiBase: butyrolactone-V (**6**) [44,45], 4-hydroxy-2-[2-(1-hydroxy-1-methyl-ethyl)-2,3-dihydro-benzofuran-5-ylmethyl]-3-(4-hydroxy-phenyl)-5-oxo-2,5-dihydrofuran-2-carboxylic acid methyl ester (**8**) [21] and butyrolactone-III (**9**) [19].

The structure was confirmed by detailed 2D experiments; H,H COSY and HMBC (Figure 4) and comparison with literature as butyrolactone-V (**6**) [25,42,43]. Butyrolactone-V was reported to exhibit a moderate antimalarial activity against the malarial parasite *Plasmodium falciparum* K1 (IC50 7.9 μ g/mL) [45].

2.3.7. 4,4'-Dihydroxypulvinone (Aspulvinone E) (7)

Compound **7** was obtained with a molecular weight of 296 Dalton ($C_{17}H_{12}O_5$) by HRESI MS, bearing 12 double bond equivalents. The 1H NMR spectrum of **7** showed five signals in the aromatic region for 9H (δ 8.06-5.88), representing two 1,4-disubstituted phenolic residues ($J \sim 8.6$ Hz). The fifth signal (1H) was shown as singlet at δ 5.88. Based on the revealed spectroscopic data and molecular formula and search in AntiBase, two alternatives, 4,4'-dihydroxypulvinone (**7**) and Gyrocyanin (**10**) were displayed. However, the chemical shift of the singlet methine in compound **10** has high field shifting (δ 4.96), which was not matching with our revealed spectral data, establishing the structure as 4,4'-dihydroxypulvinone (**7**) [46].



2.4. Biological activities

Activity patterns of the mycelial and supernatant extracts produced by fungal strain *A. flavipes* MM2 against set of microorganisms namely, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Candida albicans* and *Aspergillus niger* were carried out using agar disc method (25 µg/disc, Ø 5 mm). In accordance, both extracts showed high antibacterial (16-14 mm) and moderate anti-yeast and antifungal (10-14 mm) activities (Table 1).

Alternatively, the isolated compounds **1-7** were tested against *Bacillus subtilis*, *S. aureus*, *Streptomyces viridochromogenes* (Tü 57), *Escherichia coli*, *C. albicans*, *Mucor miehi*, *Chlorella vulgaris*, *Chlorella sorokiniana*, *Scenedesmus subspicatus*, *Rhizoctonia solani* and *Pythium ultimum* (40 µg/disc, Ø 9 mm). According to this study, only four compounds (**1**, **2**, **4**, **7**) were active. Ergosterol (**1**) was highly and moderately active against *S. aureus* and *B. subtilis*. Compounds **7**, **4** and **3** showed high and moderate activity against *S. aureus*. Finally, the whole studied compounds were tested against brine shrimp (10 µg/mL) for cytotoxic activities, exhibiting no cytotoxicity except ergosterol (**1**), which showed 100% cytotoxicity after 15 h (Table 2).

3. Experimental

NMR spectra were measured on Varian Unity 300 and Varian Inova 600 spectrometers. Electron spray ionization mass spectrometry (ESI HRMS): Finnigan LCQ ion trap mass spectrometer coupled with a Flux Instruments (Basel, Switzerland) quaternary pump Rheos 4000 and a HP 1100 HPLC (nucleosil column EC 125/2, 100-5, C 18) with autosampler (Jasco 851-AS, Jasco Inc., Easton, MD, USA) and a Diode Array Detector (Finnigan Surveyor LC System). High-resolution mass spectra (HRMS) were recorded by ESI MS on an Apex IV 7 Tesla Fourier-Transform Ion Cyclotron Resonance Mass Spectrometer (Bruker Daltonics, Billerica, MA, USA). EI MS at 70 eV with Varian MAT 731, Varian 311A, AMD-402, high-resolution with perflurokerosine as standard. R_f values were measured on Polygram SIL F/UV₂₅₄ (Merck, pre-coated sheets). Size exclusion chromatography was done on Sephadex LH-20 (Pharmacia).

3.1. Isolation and taxonomy of the producing strain

The terrestrial *A. flavipes* MM2, which was identified according to the Raper and Fennel [14], has been

isolated from rice hulls sample by placing the rice hulls over water agar medium (g/L): Agar-agar (20) and water (100%) with incubation at 28°C for 7 days the developing colony was transferred to Czapeks agar with incubation at 28°C for 10 days. Bright whit-faint yellow colonies with a brown straining background of the fungal strain were grown. The colonies are growing rather slowly, showing whitish from conidial masses, with brownish conidiophores shining through, reverse yellow-brown to red brown Conidial heads spas, loosely columnar, conidiophores smooth-walled, pale yellow to light brown 2.4-3.2 µm diameter. According to its morphological and microscopic characteristics and comparison with literature, the fungal strain was assigned as *A. flavipes* MM2 [14]. The strain is deposited in Dr Mohammad Magdy El Metwally collection in Microbiology Department, Soil & Water and Environment Research Institute, ARC, Giza, Egypt.

3.2. Fermentation, extraction and isolation

Small pieces (1 cm²) of well grown sub-cultures of *A. flavipes* MM2 were inoculated into thirty 1-L Erlenmeyer flasks, each containing 300 mL of sterilized Czapeck-Dox medium (g/L): Sucrose (30), NaNO₃ (3), K₂HPO₄ (1), KCl (0.5), MgSO₄ (0.5), FeSO₄ (0.01) and distilled water (1 L) at pH = (7.3). The inoculated flasks were incubated for 10 days at 28°C and 100 rpm. After harvesting, the fungal mate and supernatant were separated by filtration. The fungal mat was then applied to maceration in methanol (3 × 0.5 L). The methanol extract was concentrated in vacuum and the remaining aqueous solution was re-extracted by ethyl acetate followed by concentration to yield 845 mg as brown crude extract. The supernatant was passed through XAD-16 column (4 × 120 cm). After washing with water, the absorbed organic extract was eluted by methanol, followed by concentration under vacuum, and the aqueous residue was re-extracted by ethyl acetate, followed by concentration in vacuo to afford 818 mg as brown crude extract.

The mycelial extract (845 mg) was subjected to fractionation using silica gel column chromatography (cyclohexane-CH₂Cl₂-MeOH) to afford 200 mg as major fraction, which was then washed by MeOH to deliver a colourless precipitate. The last precipitate was purified on Sephadex LH-20 (CH₂Cl₂/40% MeOH) to afford Ergosterol (**1**, 12 mg) as colourless solid.

Table 1 Pre-antimicrobial assays of *A. flavipes* MM2 (φ mm)

Medium no.	Inhibition zone (mm)							
	Culture filtrate extract				Cells extract			
	<i>St. aureus</i>	<i>Ps. aeruginosa</i>	<i>C. albicans</i>	<i>A. niger</i>	<i>St. Aureus</i>	<i>Ps. aeruginosa</i>	<i>C. albicans</i>	<i>A. niger</i>
Czapeck-Dox	15	16	14	12	14	14	10	10

Table 2 Antimicrobial assays of *A. flavipes* MM2 compounds (φ mm)

Compound (No.)	Inhibition zone (mm) of tested microorganisms											Brine shrimp
	<i>B. sub.</i>	<i>St. aur.</i>	<i>St. Virid.</i>	<i>E. coli</i>	<i>C. alb</i>	<i>M. miehi</i>	<i>Ch. vulg</i>	<i>Ch. Sorok</i>	<i>Sce. sub</i>	<i>R. solani</i>	<i>P. ultim</i>	
Ergosterol (1)	11	19	ND	ND	ND	ND	ND	ND	ND	ND	ND	100%
Butyrolactone I (2)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Aspulvinone H (3)	ND	11	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
6-methylsalicylic acid (4)	ND	15	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Terrien (5)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Butyrolactone-V (6)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
4,4'-dihydroxypulvinone (7)	ND	18	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND

The filtrate crude extract (818 mg) was fractionated on silica gel column and eluted by cyclohexane-CH₂Cl₂-MeOH gradient to give five fractions (I-V). Fraction FIII was further fractionated using Sephadex LH-20 column (MeOH) to afford two sub-fractions, FIIIa (44 mg) and FIIIb (73 mg). Purification of FIIIa by Sephadex LH-20 (MeOH) afforded a colourless solid of butyrolactone-I (2, 4 mg). PTLC purification (CH₂Cl₂/5%MeOH) of FIIIb followed by Sephadex LH-20 (MeOH) afforded Aspulvinone H (3) as colourless solid (3 mg). A further fractionation of FIV on Sephadex LH-20 (MeOH) led to sub-fractions FIVa (35 mg) and FIVb (120 mg). Purification of sub-fraction FIVa using Sephadex LH-20 (MeOH), PTLC (CH₂Cl₂/5% MeOH), and then Sephadex LH-20 (MeOH) resulted in 6-methylsalicylic acid (4, 10 mg) as colourless solid. Sub-fraction FIVb was purified on Sephadex LH-20 (MeOH) to afford Terrien (5, 10 mg) and butyrolactone-V (6, 2 mg) as two colourless solids. Finally, fraction FV was purified using two subsequent Sephadex LH-20 columns (MeOH) to give a yellow solid of 4,4'-dihydroxypulvinone (7, 4 mg).

3.2.1. Ergosterol; ergosta-5,7,22-triene-3β-ol (1)

C₂₈H₄₄O (396), colourless solid, UV-absorbing, turned violet with anisaldehyde/sulphuric acid, *R_f* = 0.46 (CH₂Cl₂/5%MeOH); ¹H NMR (CDCl₃, 300 MHz): δ = 5.57 (dm, 1H, H-6), 5.38 (dm, 1H, H-7), 5.17 (m, 2H, H-22,23), 3.62 (m, 1H, H-3), 2.46 (dm, 1H, H-5), 2.35 (m, 2H, H-20, 24), 2.09-1.93 (m, 3H), 1.92-1.89 (m, 4H), 1.88-1.55 (m, 4H), 1.50-1.40 (m, 3H), 1.38-1.16 (m, 3H), 1.02 (d, *J* = 7.2, 3H, CH₃-21), 0.93 (s, 3H, CH₃-19), 0.91 (d, *J* = 7.2, 3H, CH₃-28), 0.82 (d, *J* = 6.8, 3H, CH₃-27), 0.80 (d, *J* = 6.8, 3H, CH₃-26), 0.61 (s, 3H, CH₃-18); ¹³C NMR (CDCl₃, 75 MHz): δ = 141.3 (C_q-8), 139.8 (C_q-5), 135.5 (CH-22), 131.9 (CH-23), 119.6 (CH-7), 116.3 (CH-6), 70.4 (CH-3), 55.7 (CH-17), 54.5 (CH-14), 46.2 (CH-9), 42.8 (C_q-13), 42.8 (CH-24), 40.7 (CH₂-4), 40.4 (CH-20), 39.1 (CH₂-12), 38.4 (CH₂-1), 37.0 (C_q-10), 33.1 (CH-25), 32.0 (CH₂-2), 28.3 (CH₂-16), 23.0 (CH₂-11), 21.1 (CH₂-15), 21.1 (CH₃-21), 19.9 (CH₃-27), 19.6 (CH₃-26), 17.6 (CH₃-28), 16.2 (CH₃-19), 12.0 (CH₃-18); EI-MS (70 eV): *m/z* (%) = 396 ([M]⁺, 87), 378 ([M-H₂O]⁺,

12), 363 ([M-(H₂O+CH₃)]⁺, 100), 271 (25), 253 (52), 211 (33).

3.2.2. Butyrolactone-I (2)

C₂₄H₂₄O₇ (424), colourless solid, UV-absorbing, turned violet with anisaldehyde/sulphuric acid, *R_f* = 0.39 (CH₂Cl₂/5% MeOH); ¹H NMR (CD₃OD, 300 MHz): δ = 7.57 (d, *J* = 8.8 Hz, 2H, H-2',6'), 6.86 (d, *J* = 8.8 Hz, 2H, H-3',5'), 6.50 (dd, *J* = 7.1, 2.0 Hz, 1H, H-6"), 6.48 (d, *J* = 8.1 Hz, 1H, H-5"), 6.40 (d, *J* = 1.7, 1H, H-2"), 5.05 (t, *J* = 3.7 Hz, 1H, H-8"), 3.76 (s, 3H, 7-OCH₃), 3.42 (d, *J* = 3.9, 2H, CH₂-5), 3.06 (d, *J* = 7.3 Hz, 2H, CH₂-7"), 1.65 (s, 3H, CH₃-10"), 1.56 (s, 3H, CH₃-11"); ¹³C NMR (CD₃OD, 75 MHz): δ = 171.6 (C_q-6), 170.3 (C_q-1), 159.3 (C_q-4'), 155.0 (C_q-4"), 139.6 (C_q-3), 133.0 (C_q-9"), 132.4 (CH-2"), 130.4 (CH-2',6'), 129.8 (CH-6"), 129.2 (C_q-3"), 125.0 (C_q-1"), 123.1 (C_q-1'), 123.6 (CH-8"), 116.6 (CH-3',5'), 115.0 (CH-5"), 86.8 (C_q-4), 53.8 (OCH₃-7), 39.6 (CH₂-5), 28.7 (CH₂-7"), 25.9 (CH₃-10"), 17.8 (CH₃-11"); -(+)ESI MS: *m/z* (%) = 447 ([M+Na]⁺, 81), 871 ([2M+Na]⁺, 100); -(-)ESI MS: *m/z* (%) = 423 ([M-H]⁻, 13), 847 ([2M-H]⁻, 4); (+)-HRESI: *m/z* = 447.1414 [M+Na]⁺ (calc. 447.1414 for C₂₄H₂₄NaO₇); (-)-HRESI: *m/z* = 423.1435 [M-H]⁻ (calc. 423.1449 for C₂₄H₂₃O₇).

3.2.3. Aspulvinone H (3)

C₂₇H₂₈O₅ (432), colourless solid, UV-blue fluorescent, turned yellow with anisaldehyde/sulphuric acid, *R_f* = 0.62 (CH₂Cl₂/10% MeOH), ¹H NMR (CD₃OD, 300 MHz): δ = 7.81 (d, *J* = 1.8 Hz, 1H, H-2'), 7.68 (m, 1H, H-6'), 7.59 (m, 1H, H-6"), 7.44 (d, *J* = 1.6 Hz, H-2"), 6.73 (m, 2H, H-5',5"), 6.22 (s, H-5), 5.36 (m, 2H, H-8',8"), 3.40-3.00 (m, 4H, H_{2a}, b-7', H_{2a}, b-7"), 1.75 (m, 12H, H₃-10',11',10",11"); -(+)ESI MS: *m/z* (%) = 455 ([M+Na]⁺, 56), 477 ([M+2Na-H]⁺, 100), 887 ([2M+Na]⁺, 5); -(-)ESI MS: *m/z* (%) = 431 ([M-H]⁻, 100), 863 ([2M-H]⁻, 4), (+)-HRESI: *m/z* = 455.1808 [M+Na]⁺ (calc. 455.1829 for C₂₇H₂₈NaO₅); (-)-HRESI: *m/z* = 431.1860 [M-H]⁻ (calc. 431.1864 for C₂₇H₂₇O₅).

3.2.4. 6-Methylsalicylic acid (4)

C₈H₈O₃ (152), colourless solid, UV-absorbing, *R_f* = 0.24 (CH₂Cl₂/5%MeOH); ¹H NMR (CD₃OD, 300 MHz): δ = 7.07 (t, *J* = 7.7 Hz, 1H, 4-H), 6.63 (d, *J* = 8.2 Hz, 1H, 3-

H), 6.59 (d, $J = 7.5$ Hz, 1H, 5-H), 2.56 (s, 3H, CH₃-7); ¹³C NMR (CD₃OD, 75 MHz): $\delta = 176$ (C_q-8), 162.7 (C_q-2), 142.7 (C_q-6), 132.1 (CH-4), 122.9 (CH-3), 119.5 (C_q-1), 115.1 (CH-5), 23.3 (CH₃-7); -(+)ESI MS: m/z (%) = 175 ([M+Na]⁺, 25), 371 ([2M+3Na-2H]⁺, 55); (-)ESI MS: m/z (%) = 151 ([M-H]⁻, 100), 303 ([2M-H]⁻, 4).

3.2.5. Terrine (5)

C₈H₁₀O₃ (154), colourless solid, UV-absorbing, turned dark green on spraying with anisaldehyde/sulphuric acid, $R_f = 0.51$ (CH₂Cl₂/10%MeOH); ¹H NMR (CD₃OD, 300 MHz): $\delta = 6.82$ (ddd, $J = 13.7, 8.9, 6.8$ Hz, 1H, H-2), 6.42 (dd, $J = 15.8, 1.1$ Hz, 1H, H-3), 5.99 (s, 1H, H-5), 4.67 (d, $J = 2.4$ Hz, 1H, H-8), 4.07 (d, $J = 2.7$ Hz, 1H, H-7), 1.97 (dd, $J = 6.8, 1.4$ Hz, 3H, 1-CH₃); ¹³C NMR (CD₃OD, 75 MHz): $\delta = 205.6$ (C_q-6), 170.8 (C_q-4), 141.8 (CH-2), 126.4 (CH-3), 125.9 (CH-5), 82.4 (CH-7), 78.1 (CH-8), 19.5 (CH₃-1); -(+)ESI MS: m/z (%) = 177 ([M+Na]⁺, 62), 331 ([2M+Na]⁺, 100); (-)ESI MS: m/z (%) = 153 ([M-H]⁻, 34), 307 ([2M-H]⁻, 4); (+)-HRESI MS: m/z 177.0528 [M+Na]⁺ (calc. 177.0522 for C₈H₁₀NaO₃); (-)-HRESI MS: m/z 153.0553 [M-H]⁻ (calc. 153.0557 for C₈H₉O₃).

3.2.6. Butyrolactone-V (6)

C₂₄H₂₄O₈ (440), colourless solid, UV-absorbing, turned pink with anisaldehyde/sulphuric acid, $R_f = 0.12$ (CH₂Cl₂/5% MeOH), ¹H NMR (CD₃OD, 300 MHz): $\delta = 7.54$ (d, $J = 8.8$ Hz, 2H, H-2',6'), 6.85 (d, $J = 8.8$ Hz, 2H, H-3',5'), 6.48 (m, 3H, H-2'',5'',6''), 5.02 (dd, $J = 5.2, 2.0$ Hz, 1H, H-8''), 3.77 (s, 3H, OCH₃-7), 3.40 (s, 2H, CH₂-5), 2.80 (dd, $J = 5.2, 16.9$ Hz, 2H, CH₂-7''), 1.25 (s, 3H, CH₃-10''), 1.16 (s, 3H, CH₃-11''); ¹³C NMR (CD₃OD, 75 MHz): $\delta = 171.5$ (C_q-6), 170.3 (C_q-1), 159.4 (C_q-4'), 153.3 (C_q-4''), 139.6 (C_q-3), 132.9 (CH-2''), 130.4 (CH-2',6'), 130.4 (CH-6''), 120.5 (C_q-3''), 126.0 (C_q-1'), 123.1 (C_q-1''), 116.6 (CH-3',5'), 117.2 (CH-5''), 86.8 (C_q-4), 78.0 (C_q-9''), 70.4 (CH-8''), 53.9 (OCH₃-7), 39.5 (CH₂-5), 32.0 (CH₂-7''), 25.8 (CH₃-10''), 20.9 (CH₃-11''); -(+)ESI MS: m/z (%) = 441 ([M+H]⁺, 30), 463 ([M+Na]⁺, 57.5), 881 ([2M+H]⁺, 25), 903 ([2M+Na]⁺, 50); (-)ESI MS: m/z (%) 439 ([M-H]⁻, 3); (+)-HRESI: m/z 463.1370 [M+Na]⁺ (calc. 463.1363 for C₂₄H₂₄NaO₈); (-)-HRESI: m/z 439.1399 [M-H]⁻ (calc. 439.1389 for C₂₄H₂₃O₈).

3.2.7. 4,4'-Dihydroxypulvinone (7)

C₁₇H₁₂O₅ (296), colourless solid, UV yellow fluorescence, $R_f = 0.15$ (CH₂Cl₂/5% MeOH); ¹H NMR (DMSO-d₆, 300 MHz): $\delta = 9.42$ (brs, 1H, 4'-OH), 8.70 (brs, 1H, 4''-OH), 8.06 (d, $J = 8.6$ Hz, 2H, H-2',6'), 7.51 (d, $J = 8.7$ Hz, 2H, H-2'',6''), 6.75 (d, $J = 8.7$ Hz, 2H, H-3', 5'), 6.16 (d, $J = 8.7$ Hz, 2H, H-3'', 5''), 5.88 (s, 1H, H-5); ¹³C NMR (DMSO-d₆, 300 MHz): $\delta = 156.1$ (C_q-4',4''), 152.4 (C_q-4), 130.4 (CH-2',2'',6',6''), 126.1 (C_q-1', 1''), 124.6 (CH-5), 115.3 (CH-3',5'), 114.1 (CH-3'',5''); -(+)ESI MS: m/z (%) = 319 ([M+Na]⁺, 20), 314 ([M+2Na-H]⁺, 30); (-)ESI MS: m/z (%) = 295 ([M-H]⁻,

100); (+)-HRESI MS: m/z 319.0587 [M+Na]⁺ (calc. 319.0577 for C₁₇H₁₂NaO₅). (-)-HRESI: m/z 295.0616 [M-H]⁻ (calc. 295.0612 for C₁₇H₁₁O₅).

3.3. Biological activities

3.3.1. Antimicrobial activity

Antimicrobial assays were conducted utilizing the disc-agar method [47]. This has been carried out against diverse sets of microorganisms. *A. flavipes* MM2 extract was dissolved in CH₂Cl₂/10% MeOH at a concentration of 1 mg/mL. Aliquots of 40 μ L were soaked on filter paper discs (9 mm \varnothing , no. 2668, Schleicher & Schüll, Germany) and dried for 1 h at room temperature under sterilized conditions. The paper discs were placed on inoculated agar plates and incubated for 24 h at 38°C for bacterial and 48 h (30°C) for the fungal isolates, while the algal test strains were incubated at approximately 22°C in day light for 8-10 days. The pure compounds were examined against the test microorganisms: *B. subtilis*, *S. aureus*, *S. viridochromogenes* (Tü 57), *E. coli*, *C. albicans*, *M. miehi*, *C. vulgaris*, *C. sorokiniana*, *S. subspicatus*, *R. solani* and *P. ultimum*.

3.3.2. Brine shrimp microwell cytotoxicity assay

The cytotoxic assay was performed according to Sajid et al.'s screening [48].

Acknowledgements

The authors are deeply thankful to Prof. H. Laatsch for his Lab facilities and unlimited support. We thank Dr. H. Frauendorf and Mr. R. Machinek for the spectral measurements. We appreciate to Miss F. Lissy for testing biological activity and Mr. A. Kohl for his technical assistance. This research work is financed by German Egyptian Scientific Projects (GESP) No. 7.

Author details

¹Division of Pharmaceutical Industries, Chemistry of Natural Compounds Department, National Research Centre, El-Beheos st. 33, Dokki, Cairo 12622, Egypt ²Microbial Activity Unit, Microbiology Department, Soil & Water and Environment Research Institute, ARC, Giza, Egypt ³Institute of Organic and Biomolecular Chemistry, University of Göttingen, Tammannstrasse 2, D-37077 Göttingen, Germany ⁴Pharmacognosy Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Competing interests

The authors declare that they have no competing interests.

Received: 18 November 2011 Accepted: 1 March 2012

Published: 1 March 2012

References

1. Faulkner DJ (2006) Marine bacterial metabolites. In: Proksch P, Muller WEG (eds) *Frontiers in marine biotechnology*. Horizon Bioscience pp 225-288
2. Laatsch H (2010) A data base for rapid structural determination of microbial natural products and annual updates. *Chemical Concepts*, Weinheim, Germany
3. Larsen TO, Smedsgaard J, Nielsen KF, Hansen ME, Frisvad JC (2005) Phenotypic taxonomy and metabolite profiling in microbial drug discovery. *Nat Prod Rep* 22:672-695. doi:10.1039/b404943h.
4. Hassan AEHA (2007) Novel natural products from endophytic fungi of Egyptian medicinal plants—chemical and biological characterization. Dissertation, Düsseldorf, Germany
5. Butler MS (2004) The role of natural product chemistry in drug discovery. *J Nat Prod* 67:2141-2153. doi:10.1021/np040106y.

6. Rasmussen TB, Skinderso ME, Bjarsholt T, Phipps RK, Christensen KB, Andersen JB, Koch B, Larsen TO, Hentzer M, Hoiby N, Givskov M (2005) Identity and effects of quorum-sensing inhibitors produced by *Penicillium* species. *Microbiology* 151:1325–1340. doi:10.1099/mic.0.27715-0.
7. Li JY, Strobel GA (2001) Jesterone and hydroxyjesterone antiomycete cyclohexenone epoxides from the endophytic fungus: Pestalotiopsis jesteri. *Phytochemistry* 57:261–265. doi:10.1016/S0031-9422(01)00021-8.
8. Brady SF, Clardy J (2000) CR377, a new pentaketide antifungal agent isolated from an *endophytic* fungus. *J Nat Prod* 63:1447–1448. doi:10.1021/np990568p.
9. Singh SB, Zink DL, Guan Z, Collado J, Pelaez F, Felock PJ, Hazuda DJ (2003) Isolation, structure and HIV-1 integrase inhibitory activity of xanthoviridicatin E and F two novel fungal metabolites produced by *Penicillium chrysogenum*. *Helv Chim Acta* 86:3380–3385. doi:10.1002/hlca.200390281.
10. Zhang HW, Song YC, Tan RX (2006) Biology and chemistry of endophytes. *Nat Prod Rep* 23:753–771. doi:10.1039/b609472b.
11. Song YC, Li H, Ye YH, Shan CY, Yang YM, Tan RX (2004) Endophytic naphthopyrone metabolites are co-inhibitors of xanthine oxidase, SW1116 cell and some microbial growths. *FEMS Microbiol Lett* 241:67–72. doi:10.1016/j.femsle.2004.10.005.
12. Lubertozzi D, Keasling JD (2009) Developing *Aspergillus* as a host for heterologous expression. *Biotechnol Adv* 27:53–75. doi:10.1016/j.biotechadv.2008.09.001.
13. Zhang Z (2009) A new species of *Aspergillus*. *Int J Biol* 1:78–80
14. Raper KB, Fennel DI (1965) The genus *Aspergillus*. Williams and Wilkins Baltimore. USA
15. Liebermann C (1885) Ueber das oxychinoterpen, *Berichte*. 18:1803–1807
16. Mourao F, Umeo SH, Takemura OS, Linde GA, Colauto NB (2011) Antioxidant activity of *Agaricus brasiliensis basidiocarps* on different maturation phases. *Braz J Microbiol* 42:197–202. doi:10.1590/S1517-83822011000100024.
17. Dissanayake DP, Abeytunga DTU, Vasudewa NS, Ratnasooriya WD (2009) Inhibition of lipid peroxidation by extracts of *Pleurotus ostreatus*. *Pharmacogn Mag* 5:266–271
18. Chen A, Chen H, Shao Y, Fan M (2009) Active components and free radical scavenging activity of fermented mycelia and broth of *Paecilomyces tenuipes*. *Shipin Kexue* 30:25–28
19. Han X, Lin Z, Tao H, Liu P, Wang Y, Zhu W (2009) Cytotoxic metabolites from symbiotic fungus *Penicillium* sp. HK13-8 with *Rhizophora stylosa*. *Zhongguo Haiyang Yaowu* 28:11–16
20. Yan D, Bao HY, Bau T, Li Y, Kim YH (2009) Antitumor components from *Naematoloma fasciculare*. *J Microbiol Biotechnol* 19:1135–1138
21. Nitta K, Fujita N, Yoshimura T, Arai K, Yamamoto U (1983) Metabolic products of *Aspergillus terreus*. IX: biosynthesis of butyrolactone derivatives isolated from strain IFO 8835 and 4100. *Chem Pharm Bull* 31:1528–1533. doi:10.1248/cpb.31.1528.
22. Zain ME, Awaad AS, Al-Jaber NA, Maitland DJ (2008) New phenolic compounds with antifungal activity from *Aspergillus terreus* isolated from desert soil. *J Saudi Chem Soc* 12:107–113
23. Nuclear P, Sommit D, Boonyuen N, Pudhom K (2010) Butenolide and furandione from an endophytic *Aspergillus terreus*. *Chem Pharm Bull* 58:1221–1223. doi:10.1248/cpb.58.1221.
24. Rao KV, Sadhukhan AK, Veerender M, Ravikumar V, Mohan EVS (2000) Butyrolactones from *Aspergillus terreus*. *Chem Pharm Bull* 48:559–562. doi:10.1248/cpb.48.559.
25. Parvatkar RR, Souza CD, Tripathi A, Naik CG (2009) Aspernolides & Alpha; and & Beta; butenolides from a marine-derived fungus. *Aspergillus terreus*. *Phytochemistry* 70:128–132
26. Kitagawa M, Okabe T, Ogino H, Matsumoto H, Suzuki-Takahashi I (1993) Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. *Oncogene* 8:2425–2432
27. Someya A, Tanaka N, Okuyama A (1994) Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in *Xenopus* egg extracts. *Biochem Biophys Res Commun* 198:536–545. doi:10.1006/bbrc.1994.1079.
28. Kitagawa M, Higashi H, Takahashi IS, Okabe T, Ogino H (1994) A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. *Oncogene* 9:2549–2457
29. Nishio K, Ishida T, Arioka H, Kurokawa H, Fukuoka K (1996) Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. *Anticancer Res* 16(6B):3387–3395
30. Suzuki M, Hosaka Y, Matsushima H, Goto T, Kitamura T, Kawabe K (1999) Butyrolactone I induces cyclin B1 and causes G2/M arrest and skipping of mitosis in human prostate cell lines. *Cancer Lett* 138:121–130. doi:10.1016/S0304-3835(98)00381-4.
31. Ojima N, Takahashi I, Ogura K, Shuichi SS (1976) New metabolites from *Aspergillus terreus* related to the biosynthesis of aspulvinones. *Tetrahedron Lett* 13:1013–1014
32. Venkatasubbaiah P, Van Dyke CG, Chilton WS (1992) Phytotoxic metabolites of *phoma sorghina*, a new foliar pathogen of pokeweed. *Mycologia* 84:715–723. doi:10.2307/3760381.
33. Shao C, Guo Z, Peng H, Peng G, Huang Z (2007) A new isoprenyl phenyl ether compound from mangrove fungus. *Chem Nat Comp* 43:377–380. doi:10.1007/s10600-007-0142-x.
34. Yamasaki S, Nobusada M, Sasaki T, Shimada A (1999) 6-Methylsalicylic acid, an antifungal substance, produced by an unidentified fungus, No 3. *Kyushu Kyoritsu Daigaku Kogakubu Kenkyu Hokoku* 23:67–71
35. Sievertsson H, Nilsson JLG (1970) Analgesic properties of methylsalicylic acids. *Acta Pharm Suecica* 7:289–292
36. Thomas GJ (1984) Herbicidal activity of 6-methylanthranilic acid and analogs. *J Agric Food Chem* 32:747–749. doi:10.1021/jf00124a011.
37. Kubo I, Muroi H, Kubo A (1994) Naturally occurring antiacne agents. *J Nat Prod* 57:9–17. doi:10.1021/np50103a002.
38. Nielsen KF, Smedsgaard J (2003) Fungal metabolite screening: database of 474 mycotoxins and fungal metabolites for dereplication by standardised liquid chromatography-UV-mass spectrometry methodology. *J Chromatog A* 1002:111–136. doi:10.1016/S0021-9673(03)00490-4.
39. Harper JK, Mulgrew AE, Li JY, Barich DH, Strobel GA, Grant DM (2001) Characterization of stereochemistry and molecular conformation using solid-state NMR tensors. *J Am Chem Soc* 123:9837–9842. doi:10.1021/ja010997l.
40. Park SH, Kim DS, Kim WG, Ryoo IJ, Lee DH, Huh CH, Youn SW, Yoo ID, Park KC (2004) Terreirin: a new melanogenesis inhibitor and its mechanism. *Cell Mol Life Sci* 61:2878–2885. doi:10.1007/s00018-004-4341-3.
41. Hosoe T, Moriyama H, Wakana D, Itabashi T, Kawai K (2009) Inhibitory effects of dihydroterreirin and terreirin isolated from *Aspergillus novofumigatus* on platelet aggregation. *Mycotoxins* 59:75–82. doi:10.2520/myco.59.75.
42. Kim DS, Lee HK, Park SH, Lee S, Ryoo IJ (2008) Terreirin inhibits keratinocyte proliferation via ERK inactivation and G2/M cell cycle arrest. *Exp Dermatol* 17:312–317. doi:10.1111/j.1600-0625.2007.00646.x.
43. Macedo JFC, Porto ALM, Marzaioli AJ (2004) Terreirinol: a novel metabolite from *Aspergillus terreus*: structure and C labeling. *Tetrahedron Lett* 45:53–55. doi:10.1016/j.tetlet.2003.10.128.
44. Lin T, Lu C, She Y (2009) Secondary metabolites of *Aspergillus* sp. F1, a commensal fungal strain of *Trewia nudiflora*. *Nat Prod Res* 23:77–85
45. Haritakun R, Rachtawee P, Chanthaket R, Boonyuen N, Isaka M (2010) Butyrolactones from the fungus *Aspergillus terreus* BCC 4651. *Chem Pharm Bull* 58:1545–1548. doi:10.1248/cpb.58.1545.
46. Ojima N, Takenaka S, Seto S (1975) Structures of pulvinone derivatives from *Aspergillus terreus*. *Phytochemistry* 14:573–576. doi:10.1016/0031-9422(75)85131-4.
47. Burkholder P, Burkholder IM, Almodovar LR (1960) Antibiotic activity of some marine algae of Puerto Rico. *Botanica Marina* 2:149–156. doi:10.1515/botm.1960.2.1-2.149.
48. Sajid I, Fondja YCB, Shaaban KA, Hasnain S, Laatsch H (2009) Antifungal and antibacterial activities of indigenous *Streptomyces* isolates from saline farmlands: prescreening, ribotyping and metabolic diversity. *World J Microbiol Biotechnol* 25:601–610. doi:10.1007/s11274-008-9928-7.

doi:10.1186/2191-2858-2-9

Cite this article as: Nagia et al.: Four butyrolactones and diverse bioactive secondary metabolites from terrestrial *Aspergillus flavipes* MM2: isolation and structure determination. *Organic and Medicinal Chemistry Letters* 2012 2:9.